Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis

Completed · Phase 2

Conditions studied: Nephrogenic Systemic Fibrosis

In brief

The purpose of this study is to determine the efficacy of imatinib mesylate in reducing cutaneous thickening and tethering in patients with nephrogenic systemic fibrosis (NSF). The study will also work to assess the safety and tolerability of imatinib mesylate in patients with chronic kidney disease and NSF.

Key facts

Study ID

NCT00677092

Run by

Massachusetts General Hospital

People needed

12

Starts

2007-12-01

Expected to finish

2009-07-01

Last updated by the study team

2017-05-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age > 18 years
• Biopsy-proven NSF
• Ability to give consent

You may not qualify if…

• Known sensitivity to imatinib mesylate or to any of its components
• Pregnant or lactating woman
• Bullous dermatologic disease
• Aspartate aminotransferase / alanine aminotransferase (AST/ALT) >3 x upper limit of normal
• Severe congestive heart failure [New York Heart Association (NYHA) Class III or IV]
• Patients who have received Gleevec in the past 12 months

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.